Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Transcenta Holding Limited ( (HK:6628) ) has provided an announcement.
Transcenta has provided an operational update on the measures it is taking to resolve a disclaimer of opinion in its 2024 annual report, highlighting continued progress on nine key initiatives intended to strengthen its financial position and liquidity. The company is advancing term sheet-level negotiations with global and regional pharma partners and investors for its lead drug candidate osemitamab, targeting completion of one or more deals and initiation of a Phase 3 trial in 2026, while also pursuing out-licensing, joint-development arrangements and potential NewCos to fund and advance several other pipeline assets. In parallel, Transcenta is pushing diversified financing initiatives with institutional investors, has signed a non-exclusive licensing and strategic collaboration deal with EirGenix for its Highly Intensified Continuous Bioprocessing platform with potential upfront, milestone and royalty revenues, and is expanding partnerships with leading culture media and CDMO players to generate recurring technology license–linked sales and deepen its position in the global biomanufacturing supply chain.
The most recent analyst rating on (HK:6628) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Transcenta Holding Limited stock, see the HK:6628 Stock Forecast page.
More about Transcenta Holding Limited
Transcenta Holding Limited is a Cayman Islands-registered biopharmaceutical company focused on developing and commercializing novel biologic therapeutics, with a pipeline that includes lead asset osemitamab and multiple other antibody and biologic candidates. The group also operates proprietary continuous bioprocessing and cell culture technology platforms, which it is increasingly positioning for global out-licensing and strategic partnerships with pharmaceutical, biotechnology and contract manufacturing organizations.
Average Trading Volume: 1,076,973
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.03B
See more insights into 6628 stock on TipRanks’ Stock Analysis page.